JOSD1 Antibody

What is JOSD1 and what cellular functions does it regulate?

JOSD1 is a member of the Machado-Josephin family of deubiquitinating enzymes (DUBs) that shares a catalytic "Josephin" domain with other family members like ATXN3. JOSD1 functions as a cysteine protease that cleaves ubiquitin from protein substrates .

Key cellular functions regulated by JOSD1 include:

• Plasma membrane dynamics and cell motility

• Endocytosis (enhances macropinocytosis while decreasing clathrin- and caveolae-mediated endocytosis)

• Protein stability regulation through deubiquitination

• Protection against proteotoxicity in hepatocytes

• Regulation of cancer cell proliferation and metastasis

Importantly, JOSD1 is activated by ubiquitination and predominantly localizes to the plasma membrane, where it influences membrane-associated processes .

What are the optimal conditions for using JOSD1 antibodies in Western blotting?

When performing Western blotting to detect JOSD1:

• Recommended dilution: 1:500 for most commercial JOSD1 antibodies

• Expected molecular weight: 23 kDa for the native protein, with potential higher molecular weight bands (30-35 kDa) representing monoubiquitinated forms

• Sample preparation: Use RIPA buffer with protease inhibitors

• Controls: Include both positive controls (tissues known to express JOSD1 such as heart, liver, kidney, or spleen) and negative controls (JOSD1-depleted samples)

• Detection systems: Both HRP-conjugated secondary antibodies and fluorescent detection systems work effectively

For stringent analysis of JOSD1 ubiquitination status, consider denature/renature immunopurification protocols as described by researchers studying JOSD1 activation mechanisms .

How should samples be prepared for JOSD1 immunohistochemistry?

For optimal JOSD1 immunohistochemical (IHC) staining:

• Antibody dilution: 1:150 for most commercial JOSD1 monoclonal antibodies

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Blocking: 5% normal serum in PBS-T for 1 hour at room temperature

• Primary antibody incubation: Overnight at 4°C

• Scoring method: Use the histologic score (H-score) system by multiplying intensity score by the proportion of positive cells (0-300)

When interpreting results, note that JOSD1 staining is primarily observed in the cytoplasm and nucleus, with enhanced membrane localization under certain conditions .

How can I detect post-translational modifications of JOSD1, particularly its ubiquitination status?

JOSD1 is known to be regulated by monoubiquitination, which influences its activity and localization. To detect ubiquitinated JOSD1:

Method 1: Stringent denature/renature immunopurification

• Transfect cells to express tagged JOSD1 (e.g., JOSD1-V5) and HA-Ub

• Lyse cells in RIPA buffer with protease inhibitors

• Denature by adding SDS to 1% for 30 minutes

• Renature by adding 4.5% Triton X-100 for 30 minutes

• Immunoprecipitate with anti-V5 antibody

• Wash extensively with RIPA buffer

• Analyze by immunoblotting with anti-V5 and anti-HA antibodies

Method 2: Site-directed mutagenesis

• Generate the JOSD1 C36A mutant, which lacks catalytic activity

• This mutant shows different ubiquitination patterns compared to wild-type JOSD1

• The mutant is predominantly polyubiquitinated and shows altered localization

Important note: While monoubiquitinated JOSD1 localizes to the plasma membrane, the C36A mutant fails to show membrane localization, suggesting ubiquitination affects both activity and localization .

What experimental approaches can be used to study JOSD1's role in cancer cell metastasis?

Based on research showing JOSD1's involvement in cancer progression, these approaches are effective:

In vitro approaches:

• Wound healing assays: Measure migration capacity after JOSD1 knockdown or overexpression

• Transwell assays: Quantify invasion through matrigel-coated membranes

• EMT marker analysis: Examine expression of epithelial-to-mesenchymal transition markers (particularly Snail) by Western blot and qRT-PCR

In vivo approaches:

• Xenograft tumor models: Subcutaneous injection of JOSD1-modulated cancer cells

• Intravenous mouse xenograft model: To assess metastatic potential

  • Inject control or JOSD1-knockdown cells via tail vein

  • Quantify micrometastatic nodules in lungs (typically 58.0±3.7 nodules in control vs. 11.4±8.8 in JOSD1-knockdown models)

• Immunohistochemical analysis: Correlate JOSD1 and target protein expression in patient samples

Molecular mechanism investigation:

• Co-immunoprecipitation to detect JOSD1-substrate interactions

• Ubiquitination assays to assess JOSD1's deubiquitinating activity on specific targets

• Rescue experiments by re-expressing substrate proteins in JOSD1-depleted cells

How can I study the interaction between JOSD1 and its substrate proteins?

To investigate JOSD1-substrate interactions:

Co-immunoprecipitation (Co-IP):

• Co-transfect epitope-tagged JOSD1 (e.g., Myc-JOSD1) and substrate (e.g., Flag-Snail) into cells

• Lyse cells in a non-denaturing buffer containing protease inhibitors

• Perform immunoprecipitation with anti-Flag antibody

• Analyze precipitates by Western blotting for Myc-JOSD1

• Perform reciprocal IP with anti-Myc antibody and blot for Flag-substrate

• Confirm endogenous interaction using antibodies against the native proteins

Deubiquitination assays:

• Co-express HA-ubiquitin with the substrate protein and JOSD1

• Treat cells with proteasome inhibitor (e.g., MG132) to prevent degradation

• Immunoprecipitate the substrate under denaturing conditions

• Analyze ubiquitination status by anti-HA immunoblotting

• Compare ubiquitination levels in the presence of wild-type JOSD1 versus the catalytically inactive C36A mutant

Substrate stabilization analysis:

• Modulate JOSD1 expression (knockdown or overexpression)

• Measure substrate protein half-life using cycloheximide chase assays

• Monitor substrate mRNA levels by qRT-PCR to confirm post-translational regulation

• Perform rescue experiments by expressing the substrate in JOSD1-depleted cells

What is the typical subcellular localization of JOSD1 and how does it change in disease states?

JOSD1 exhibits distinct localization patterns that are functionally significant:

Normal cellular localization:

• Primarily cytoplasmic and nuclear

• Marked plasma membrane accumulation, particularly when activated by monoubiquitination

• Highest tissue expression in heart, liver, kidney, and spleen

Localization in disease states:

• In cancer cells: Aberrantly overexpressed with both cytoplasmic and nuclear localization

• In proteotoxic conditions: Enhanced membrane localization of monoubiquitinated JOSD1

• The catalytically inactive JOSD1 C36A mutant loses membrane localization

Visualization techniques:

• Immunofluorescence using anti-JOSD1 antibodies (1:150 dilution)

• Live-cell imaging with fluorescently tagged JOSD1

• Co-localization studies with membrane markers

Functional significance:
The membrane localization of JOSD1 correlates with its ability to enhance membrane dynamics, cell motility, and regulate endocytosis pathways .

How is JOSD1 expression altered in different cancer types?

JOSD1 shows distinctive expression patterns across cancer types:

Expression analysis methods:

• Tissue microarray analysis: Scored using H-score (0-300)

• TCGA data mining: Shows elevated mRNA expression in multiple cancer types

• Survival analysis: Kaplan-Meier analysis shows correlation between high JOSD1 expression and poor clinical outcomes

The prognostic value of JOSD1 makes it a potential biomarker for cancer progression and therapeutic target.

Why might I observe multiple bands when performing Western blot for JOSD1?

Multiple bands in JOSD1 Western blots are common and may represent:

• Monoubiquitinated JOSD1: Higher molecular weight band (~30-35 kDa) compared to native JOSD1 (23 kDa)

  • This form is functionally significant as it represents activated JOSD1

• Polyubiquitinated JOSD1: Multiple high molecular weight bands

  • More commonly observed with the catalytically inactive C36A mutant

• Other post-translational modifications: Phosphorylation or SUMOylation may cause band shifts

• Splice variants: Alternative splicing may generate different isoforms

Verification approaches:

• Treatment with deubiquitinating enzyme USP2 to remove ubiquitin modifications

• Hydroxylamine treatment to cleave oxyester linkages in non-lysine ubiquitination

• Comparing wild-type vs. C36A mutant JOSD1 band patterns

• Stringent denaturing conditions during sample preparation to disrupt protein complexes

Note that higher molecular weight forms of JOSD1 are neither sensitive to USP2 nor hydroxylamine treatment in some experimental systems, suggesting complex regulation .

What controls should I include when performing JOSD1 knockdown or overexpression experiments?

For robust JOSD1 modulation studies:

Essential controls for knockdown experiments:

• Non-targeting shRNA/siRNA: To control for non-specific effects of the RNA interference process

• Multiple shRNA/siRNA sequences: To control for off-target effects

• Rescue controls: Re-expression of shRNA-resistant JOSD1 to confirm phenotype specificity

• Verification of knockdown efficiency: By Western blot and qRT-PCR

• Substrate expression analysis: To confirm downstream effects (e.g., Snail, SOCS1)

Controls for overexpression studies:

• Empty vector transfection: To control for transfection effects

• Catalytically inactive mutant (C36A): To distinguish enzymatic vs. scaffolding functions

• Expression level verification: Western blot to confirm comparable expression levels

• Subcellular localization confirmation: Immunofluorescence to verify proper localization

• Functional readouts: Assessment of relevant cellular processes (e.g., proliferation, migration)

Experimental validation approaches:

• In vitro: Colony formation, EdU incorporation, wound healing, transwell assays

• In vivo: Xenograft models with quantification of tumor growth and metastasis

• Molecular readouts: qRT-PCR of target genes, protein stability analyses

What are the most effective methods to study JOSD1's protective role in hepatic proteotoxicity?

Based on recent research , these approaches are recommended:

Cell culture models:

• Proteasome inhibition: Treat hepatocytes or HepG2 cells with proteasome inhibitors (e.g., MG132, Bortezomib)

• JOSD1 modulation: Knockdown using siRNA/shRNA or overexpression of wild-type vs. C36A mutant

• Viability assessment: Use LIVE/DEAD® Viability/Cytotoxicity Kit

• Apoptosis measurement: Caspase 3/7 substrate activity assay and flow cytometry

• SOCS1 interaction: Co-IP and deubiquitination assays to study JOSD1-SOCS1 interaction

Primary cell verification:

• Isolate primary mouse hepatocytes

• Perform gain and loss of function studies with JOSD1

• Verify protection against proteotoxicity

In vivo models:

• Adenovirus-mediated gene transfer:

  • Generate adenovirus carrying JOSD1 or shJOSD1

  • Purify using adenovirus purification kits

  • Determine viral titer spectrophotometrically

• Bortezomib challenge:

  • Administer proteasome inhibitor Bortezomib to induce liver injury

  • Assess hepatoprotection by measuring:

    • Serum liver enzymes

    • Histopathological changes

    • Apoptotic markers (Cleaved Caspase 3 staining)

• Mechanistic confirmation:

  • Verify SOCS1 expression and stability

  • Compare wild-type JOSD1 vs. enzymatically inactive C36A mutant effects

How can JOSD1 antibodies be used to evaluate patient prognosis in cancer studies?

JOSD1 has emerged as a prognostic marker in several cancers. Here's how to leverage JOSD1 antibodies for patient stratification:

Tissue microarray analysis:

• Construct tissue microarrays from patient tumor samples and paired normal tissues

• Perform IHC using validated JOSD1 antibodies (1:200 dilution)

• Score expression using the H-score method (intensity × proportion of positive cells, 0-300)

• Correlate with clinicopathological features and survival data

Prognostic indicators to assess:

Statistical analysis approaches:

• Kaplan-Meier survival analysis to compare high vs. low JOSD1 expression groups

• Multivariate Cox regression to assess independent prognostic value

• Correlation analysis with established cancer biomarkers

What are the key methodological approaches for investigating JOSD1's role in the Hippo/YAP pathway in cancer?

Recent research has uncovered JOSD1's role in regulating the Hippo/YAP pathway in colon cancer . Key methodological approaches include:

Correlation analysis:

• Perform IHC on patient samples for both JOSD1 and YAP

• Analyze correlation between expression patterns

• Associate with clinical characteristics and outcomes

Mechanistic studies:

• YAP regulation assessment:

  • Examine YAP protein levels after JOSD1 knockdown or overexpression

  • Monitor YAP mRNA levels to confirm post-translational regulation

  • Measure YAP target gene expression (CTGF, CYR61) by qRT-PCR

  • Perform TEAD-responsive element luciferase assay to measure YAP activity

• Functional validation:

  • EdU incorporation assay to measure proliferation

  • Wound healing and transwell experiments for migration/invasion

  • Flow cytometry analysis for apoptosis assessment

  • Long-term clonogenesis experiments

  • Xenograft mouse models with IHC analysis for Ki67

• Rescue experiments:

  • Deplete JOSD1 and overexpress YAP to determine if YAP can rescue JOSD1 depletion phenotypes

  • Compare tumor growth in vivo with JOSD1 knockdown alone versus JOSD1 knockdown + YAP overexpression

This comprehensive approach can determine whether JOSD1 functions through YAP regulation in your cancer model of interest.

How can I investigate JOSD1's potential role in non-lysine deubiquitination?

Recent research suggests that JOSD1 might belong to a class of DUBs capable of cleaving ubiquitin from non-lysine residues (serine/threonine) . To investigate this:

Model substrate approach:

• Generate model substrates with ubiquitin linked to different amino acids (lysine, serine, threonine)

• Incubate with purified JOSD1 enzyme

• Monitor deubiquitination activity using gel-based assays or fluorogenic substrates

• Compare activity against different linkage types

Site-directed mutagenesis:

• Identify potential ubiquitination sites in substrates of interest

• Generate mutants where lysines are replaced with arginines

• If ubiquitination persists, investigate serine/threonine residues

• Create serine/threonine to alanine mutations and assess ubiquitination status

Linkage-specific analysis:

• Use hydroxylamine treatment to cleave oxyester bonds (typical of serine/threonine ubiquitination)

• Compare with the effects of enzymatic deubiquitination by JOSD1

• Employ mass spectrometry to identify precise ubiquitination sites and linkage types

This research direction could reveal novel JOSD1 functions and expand our understanding of non-conventional ubiquitination in cellular regulation .

What approaches can be used to study JOSD1's role in the antiviral response?

Research indicates that JOSD1 can inhibit IFN-1 induced signaling and antiviral responses by stabilizing SOCS1 . To investigate this function:

Virus infection models:

• Establish cell systems with JOSD1 overexpression or knockdown

• Challenge with various viruses

• Assess viral replication, cytopathic effects, and viral titers

• Measure IFN-1 pathway activation (phospho-STAT1/2, ISG expression)

SOCS1 interaction studies:

• Perform co-IP to confirm JOSD1-SOCS1 physical interaction

• Assess SOCS1 ubiquitination status after JOSD1 modulation

• Verify JOSD1's ability to cleave K48-ubiquitin chains from SOCS1

• Measure SOCS1 protein stability in JOSD1-modulated cells

Pathway analysis:

• Examine JAK-STAT pathway components after JOSD1 modulation

• Monitor ISG (Interferon Stimulated Gene) expression via qRT-PCR

• Assess antiviral state establishment using reporter systems

• Determine if SOCS1 depletion abolishes JOSD1's effects on IFN signaling

These approaches would help establish JOSD1's role in immune regulation and potential as a target for modulating antiviral responses.